SCCA Biomarker Skin Condition Evaluation via ELISA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biochemical markers for evaluating skin conditions such as parakeratosis, which is characterized by abnormal proliferation and differentiation of epidermal cells, and are unclear about the mechanisms behind these conditions.
Innovation Solution
The method involves using squamous cell carcinoma antigen (SCCA), specifically the expression of SCCA-1 and SCCA-2, as markers for evaluating skin conditions by measuring their levels in the skin stratum corneum using enzyme-linked immunosorbent assay (ELISA) with SCCA-specific antibodies, particularly through tape stripping to obtain skin samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If SCCA expression is measured in skin stratum corneum using ELISA, then measurement precision of skin condition evaluation is improved, but device complexity increases due to requiring specific antibodies and ELISA equipment
Solution Approach 1:
The patent uses SCCA-specific antibodies as intermediaries to detect SCCA expression levels in skin stratum corneum. The antibodies specifically bind to SCCA, enabling precise measurement of skin conditions through ELISA. This intermediary approach allows accurate detection of parakeratosis and other skin conditions without requiring direct observation or complex imaging systems.
2Ease of operation
If tape stripping method is used to obtain skin samples, then ease of operation is improved as it is non-invasive, but manufacturing precision of sample collection deteriorates due to variability in sample acquisition
Solution Approach 1:
The tape stripping method allows the skin itself to provide the sample through a simple adhesive removal process. The stratum corneum naturally adheres to the tape when applied and removed, requiring minimal operator skill while obtaining sufficient material for SCCA measurement. This self-service approach maintains ease of operation while providing adequate samples for reliable ELISA analysis.
3Reliability
If SCCA is used as a marker for skin conditions, then reliability of skin condition diagnosis is improved, but loss of information occurs because SCCA was traditionally only associated with cancer diagnosis
Solution Approach 1:
The patent establishes SCCA as a universal marker that serves multiple functions: traditional cancer diagnosis and new skin condition evaluation including parakeratosis, psoriasis, and atopic dermatitis. By demonstrating SCCA's expression in various skin conditions, the invention expands the marker's applicability beyond its original cancer-specific use, allowing single-marker multi-purpose diagnostics without losing the original cancer diagnostic capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the biochemical judgment of skin conditions including roughness, skin aging, dryness, and parakeratosis caused by psoriasis or atopic dermatitis, providing a non-invasive means to assess skin health and potential issues before symptoms appear.
Implementation Method 1
The SCCA expression is preferably measured by enzyme-linked immunosorbent assay (ELISA) using SCCA-specific antibodies
Data Source
AI summary
The invention provides a method for evaluating skin condition using squamous cell carcinoma antigen (SCCA) expression in skin stratum corneum cells as a marker.